WO2003100419A1 - Procedes d'utilisation de la voie de cd163 pour moduler une reponse immunitaire - Google Patents

Procedes d'utilisation de la voie de cd163 pour moduler une reponse immunitaire Download PDF

Info

Publication number
WO2003100419A1
WO2003100419A1 PCT/NL2003/000395 NL0300395W WO03100419A1 WO 2003100419 A1 WO2003100419 A1 WO 2003100419A1 NL 0300395 W NL0300395 W NL 0300395W WO 03100419 A1 WO03100419 A1 WO 03100419A1
Authority
WO
WIPO (PCT)
Prior art keywords
ligand
molecule
agonist
antagonist
immune response
Prior art date
Application number
PCT/NL2003/000395
Other languages
English (en)
Inventor
Louis Boon
Petrus Johannes Simons
David Speijer
Ruprecht Jules Joost Van Neerven
Original Assignee
Bioceros B.V.
Macrozyme B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP02077071A external-priority patent/EP1367393A1/fr
Application filed by Bioceros B.V., Macrozyme B.V. filed Critical Bioceros B.V.
Priority to AU2003243058A priority Critical patent/AU2003243058A1/en
Publication of WO2003100419A1 publication Critical patent/WO2003100419A1/fr
Priority to US10/996,177 priority patent/US20050214871A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Physiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention a trait au domaine de l'immunologie, de la thérapie génique et de la médecine. Elle concerne notamment l'identification d'une molécule capable d'interagir avec une forme de CD163 soluble et/ou à liaison cellulaire et, en conséquence de cette interaction, une réponse immunitaire est soit mise en oeuvre, soit supprimée dans un organisme. Cette invention concerne également la préparation d'une composition pharmaceutique comprenant ladite molécule et/ou un antagoniste I et/ou un agoniste I de celle-ci, et/ou un CD163 isolé et/ou un antagoniste II ou un agoniste II de celui-ci, pour traiter ou prévenir un trouble de réponse immunitaire, tel qu'une inflammation, un cancer ou une infection, chez un individu.
PCT/NL2003/000395 2002-05-27 2003-05-27 Procedes d'utilisation de la voie de cd163 pour moduler une reponse immunitaire WO2003100419A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2003243058A AU2003243058A1 (en) 2002-05-27 2003-05-27 Methods for using the cd163 pathway for modulating an immune response
US10/996,177 US20050214871A1 (en) 2002-05-27 2004-11-23 Methods for using the CD163 pathway for modulating an immune response

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US38368902P 2002-05-27 2002-05-27
EP02077071.5 2002-05-27
US60/383,689 2002-05-27
EP02077071A EP1367393A1 (fr) 2002-05-27 2002-05-27 Procédé d'utilisation de la voie CD 163 pour la modulation d'une réponse Immunitaire

Publications (1)

Publication Number Publication Date
WO2003100419A1 true WO2003100419A1 (fr) 2003-12-04

Family

ID=29585706

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NL2003/000395 WO2003100419A1 (fr) 2002-05-27 2003-05-27 Procedes d'utilisation de la voie de cd163 pour moduler une reponse immunitaire

Country Status (2)

Country Link
AU (1) AU2003243058A1 (fr)
WO (1) WO2003100419A1 (fr)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004100995A1 (fr) * 2003-05-15 2004-11-25 Hemosol Lp Administration ciblee de composes antiviraux au moyen de bioconjugues a base d'hemoglobine
EP1742658A4 (fr) * 2004-04-23 2007-11-28 Pharmacia & Upjohn Co Llc Facteur de permissivite cellulaire pour virus, et son utilisation
WO2011039511A3 (fr) * 2009-09-29 2011-10-27 Cytoguide A/S Agents, utilisations et procédés
WO2011039510A3 (fr) * 2009-09-29 2011-10-27 Cytoguide A/S Agents, utilisations et procédés
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
US8877190B2 (en) 2006-11-30 2014-11-04 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US9062101B2 (en) 2010-08-14 2015-06-23 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US9176150B2 (en) 2003-01-31 2015-11-03 AbbVie Deutschland GmbH & Co. KG Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof
US10208109B2 (en) 2005-11-30 2019-02-19 Abbvie Inc. Monoclonal antibodies against amyloid beta protein and uses thereof
WO2021050606A1 (fr) * 2019-09-09 2021-03-18 The Children's Hospital Of Philadelphia Compositions et méthodes de traitement de troubles associés à un dysfonctionnement ou à une perte de clec16a
US11034770B2 (en) 2019-07-19 2021-06-15 Oncoresponse, Inc. Immunomodulatory antibodies and methods of use thereof
WO2022063879A1 (fr) * 2020-09-23 2022-03-31 Ablevia Biotech Gmbh Composé pour la séquestration d'anticorps indésirables chez un patient

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002032941A2 (fr) * 2000-10-16 2002-04-25 Proteopharma Aps La fonction d'un recepteur haptoglobine-hemoglobine et utilisations associees

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002032941A2 (fr) * 2000-10-16 2002-04-25 Proteopharma Aps La fonction d'un recepteur haptoglobine-hemoglobine et utilisations associees

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GRAVERSEN JONAS HEILSKOV ET AL: "CD163: A signal receptor scavenging haptoglobin-hemoglobin complexes from plasma", INTERNATIONAL JOURNAL OF BIOCHEMISTRY AND CELL BIOLOGY, vol. 34, no. 4, April 2002 (2002-04-01), pages 309 - 314, XP002255897, ISSN: 1357-2725 *
HOEGGER PETRA ET AL: "Soluble CD163 inhibits phorbol ester-induced lymphocyte proliferation", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 288, no. 4, 9 November 2001 (2001-11-09), pages 841 - 843, XP002255898, ISSN: 0006-291X *
RITTER MIRKO ET AL: "Interaction of CD163 with the regulatory subunit of casein kinase II (CKII) and dependence of CD163 signaling on CKII and protein kinase C", EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 31, no. 4, April 2001 (2001-04-01), pages 999 - 1009, XP002255899, ISSN: 0014-2980 *

Cited By (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9176150B2 (en) 2003-01-31 2015-11-03 AbbVie Deutschland GmbH & Co. KG Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof
US10464976B2 (en) 2003-01-31 2019-11-05 AbbVie Deutschland GmbH & Co. KG Amyloid β(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof
WO2004100995A1 (fr) * 2003-05-15 2004-11-25 Hemosol Lp Administration ciblee de composes antiviraux au moyen de bioconjugues a base d'hemoglobine
EP1742658A4 (fr) * 2004-04-23 2007-11-28 Pharmacia & Upjohn Co Llc Facteur de permissivite cellulaire pour virus, et son utilisation
EP2520310A1 (fr) * 2004-04-23 2012-11-07 Pharmacia & Upjohn Company LLC Facteur de permissivite cellulaire pour virus, et son utilisation
US10208109B2 (en) 2005-11-30 2019-02-19 Abbvie Inc. Monoclonal antibodies against amyloid beta protein and uses thereof
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
US10323084B2 (en) 2005-11-30 2019-06-18 Abbvie Inc. Monoclonal antibodies against amyloid beta protein and uses thereof
US10538581B2 (en) 2005-11-30 2020-01-21 Abbvie Inc. Anti-Aβ globulomer 4D10 antibodies
US9540432B2 (en) 2005-11-30 2017-01-10 AbbVie Deutschland GmbH & Co. KG Anti-Aβ globulomer 7C6 antibodies
US8877190B2 (en) 2006-11-30 2014-11-04 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US9951125B2 (en) 2006-11-30 2018-04-24 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US9359430B2 (en) 2006-11-30 2016-06-07 Abbvie Inc. Abeta conformer selective anti-Abeta globulomer monoclonal antibodies
US9394360B2 (en) 2006-11-30 2016-07-19 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
WO2011039510A3 (fr) * 2009-09-29 2011-10-27 Cytoguide A/S Agents, utilisations et procédés
US9724426B2 (en) 2009-09-29 2017-08-08 Affinicon Aps Agents, uses and methods
CN107095850A (zh) * 2009-09-29 2017-08-29 艾芬尼康有限公司 治疗剂、用途和方法
WO2011039511A3 (fr) * 2009-09-29 2011-10-27 Cytoguide A/S Agents, utilisations et procédés
US9822171B2 (en) 2010-04-15 2017-11-21 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US10047121B2 (en) 2010-08-14 2018-08-14 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US9062101B2 (en) 2010-08-14 2015-06-23 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US11034770B2 (en) 2019-07-19 2021-06-15 Oncoresponse, Inc. Immunomodulatory antibodies and methods of use thereof
US11634501B2 (en) 2019-07-19 2023-04-25 Oncoresponse, Inc. Immunomodulatory antibodies and methods of use thereof
EP4004051A4 (fr) * 2019-07-19 2023-08-23 Oncoresponse, Inc. Anticorps immunomodulateurs et leurs méthodes d'utilisation
US11827715B2 (en) 2019-07-19 2023-11-28 Oncoresponse, Inc. Human CD163 antibodies and uses thereof
WO2021050606A1 (fr) * 2019-09-09 2021-03-18 The Children's Hospital Of Philadelphia Compositions et méthodes de traitement de troubles associés à un dysfonctionnement ou à une perte de clec16a
WO2022063879A1 (fr) * 2020-09-23 2022-03-31 Ablevia Biotech Gmbh Composé pour la séquestration d'anticorps indésirables chez un patient

Also Published As

Publication number Publication date
AU2003243058A1 (en) 2003-12-12
AU2003243058A8 (en) 2003-12-12

Similar Documents

Publication Publication Date Title
JP6728257B2 (ja) バイオフィルムの除去のための組成物および方法
KR100759295B1 (ko) Ａｐｒｉｌ 수용체(ｂｃｍａ) 및 그 용도
KR102618312B1 (ko) 항muc16 항체 및 그의 용도
DK1210425T4 (en) BAFF receptor (BCMA), an immunoregulatory agent
JP2009148287A (ja) 樹状細胞のレセプター
JP2008530138A (ja) Ｉｌ−３１アンタゴニストに対するアトピー性皮膚炎の治療応答を予測する方法
AU2016365318B2 (en) Antibodies and molecules that immunospecifically bind to BTN1A1 and the therapeutic uses thereof
WO2003100419A1 (fr) Procedes d'utilisation de la voie de cd163 pour moduler une reponse immunitaire
JP6363623B2 (ja) 免疫グロブリンａのレベルを増大するための方法
US20210032350A1 (en) Antibodies to galectin-3 and methods of use thereof
WO2015120138A2 (fr) Agents modulant la signalisation rgmb-neogénine-bmp et leurs procédés d'utilisation
US8440185B2 (en) Compositions and methods for the treatment of immunologic disorders
KR20130132904A (ko) 인간 모노클로날 항체
CA3080835A1 (fr) Methodes immunotherapeutiques pour traiter et/ou prevenir le cancer du poumon
JPH09504167A (ja) ドクムギ花粉アレルゲンのｔ細胞エピトープ
US20050214871A1 (en) Methods for using the CD163 pathway for modulating an immune response
WO2011038689A1 (fr) Nouvelle cytokine humaine vstm1-v2 et son utilisation
KR100455023B1 (ko) 독보리 꽃가루 알레르겐의 t-세포 에피토프
US20070269437A1 (en) Pro-Inflammatory and Anti-Inflammatory Antibodies Against the Heparin-Binding Protein (Hbp)
CN113412130A (zh) 用于诊断和治疗癌症及其他疾病的对促肿瘤癌症相关成纤维细胞的识别和靶向
WO2013156771A1 (fr) Peptides anti-athérogènes
RU2793972C2 (ru) Иммунотерапевтический способ лечения и/или профилактики рака легких
JP2002537272A (ja) アジュバントおよび細胞成熟物質
KR101526307B1 (ko) 항염증성 약학 조성물
WO2003086457A2 (fr) Methode pour assurer le traitement ou la prophylaxie de maladies auto-immunes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP